αv vitronectin receptors in vascular-mediated disorders

Medicinal Research Reviews

Volumn 23, Issue 2, 2003, Pages 190-199

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Alpha v; Alpha v beta 3 antagonists; Angiogenesis; Integrins; Occlusion; Osteopontin; Restenosis; Vitronectin

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; 3 [[[1 [3 (1H IMIDAZOL 2 YLAMINO)PROPYL] 1H INDAZOL 5 YL]CARBONYL]AMINO] N (MESITYLSULFONYL)ALANINE; ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; BETA5 INTEGRIN; CYCLOPEPTIDE; INDAZOLE DERIVATIVE; INTEGRIN; INTEGRIN RECEPTOR; ISOXAZOLINE DERIVATIVE; L 748415; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; OSTEOPONTIN; RECEPTOR BLOCKING AGENT; SB 267268; SC 56631; SC 68448; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR; XT 199; ALPHAVBETA5 INTEGRIN;

ANGIOGENESIS; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETIC RETINOPATHY; HUMAN; NONHUMAN; RESTENOSIS; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; RECEPTORS, VITRONECTIN; VASCULAR DISEASES;

EID: 0037372226     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10031     Document Type: Review

References (65)

1. Ruoslahti E, Pierchbacker M. Arg-Gly-Asp: A versatile cell recognition sequence. Cell 1986;44:517-518.
2. Hynes RO. Integrins: Versatility, modulation and signaling in cell adhesion. Cell 1992;69:11-25.
3. Cheresh D. Integrins: Structure, function and biological properties. Adv Mol Cell Biol 1993;6:225-252.
4. Varner JA, Emerson D, Juliano R. Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Mol Biol Cell 1995;6:725-740.
5. Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91:8856-8860.
6. Meredith JE, Fazeli B, Schwartz M. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-961.
7. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;749:1157-1164.
8. Kiosses WB, Shattil SJ, Pampori N, Schwartz MA. Rac recruits high-affinity integrin alpha v beta 3 to lamellipodia in endothelial cell migration. Nat Cell Biol 2001;3:316-320.
9. Pfaff M, Tangemann K, Muller B. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha v beta 3 and alpha 5 beta 1 integrins. J Biol Chem 1994;269:20233-20238.
10. Healy J, Murayama O, Maeda T, et al. Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry 1995;34:3948-3955.
11. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from a phage display library. J Biol Chem 1993;268:20205-20210.
12. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994;124:373-380.
13. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev 1996;12:697-715.
14. Ponce ML, Nomizu M, Kleinman HK. An angiogenic laminin site and its antagonist bind through the alpha v beta 3 and alpha 5 beta 1 integrins. FASEB J 2001;15:1389-1397.
15. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-571.
16. Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecule alpha v integrin antagonists: Comparative anticancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999;19:959-968.
17. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug to tumor vasculature in a mouse model. Science 1998;279:377-380.
18. DeNardo SJ, Burke PA, Leigh BR, et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm 2000;15:71-79.
19. Lode HN, Moehler T, Xiang R, et al. Synergy between a antiangiogenic integrin alpha v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 1999;96:1591-1596.
20. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. Antagonists of inhibit retinal neovascularization in a murine model. Lab Invest 1996;75:563-573.
21. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-1822.
22. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-571.
23. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation-activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992;210:911-921.
24. Piershbache RMD, Ruoslahti E. Influence of sterochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem 1987;262:17294-17298.
25. Bach AC, Espina JR, Jackson SA, Mousa SA. Type II to Type Ib-turn swap changes specificity for integrins. J Am Chem Soc 1996;118:293-294.
26. Keenan RM, Miller WH, Kwon C, et al. Discovery of potent non-peptide vitronectin (alpha v beta 3 integrin) antagonists. J Med Chem 1997;40:2289-2292.
27. Corbett JW, Graciani NR, Mousa SA, DeGrado WF. Solid phase synthesis of a selective alpha v beta 3 integrin antagonist library. Bioorg Med Chem Lett 1997;7:1371-1376.
28. Knolle J, Breiphol G, Guba W, et al. Design and synthesis of potent and selective peptidomimetic vitronectin receptor antagonists. In: Tam JP, Kaumaya TP, editors. Peptide Chemical structure and Biology. Proceedings of the 15th American Peptide Symposiums. England: Mayflower Scientific Ltd. 1997. Abstract L102.
29. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin alpha(v) beta 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998;58:1930-1935.
30. Gould RJ, Polokoff MA, Friedman PA, et al. Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 1990;195:168-171.
31. Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin Hematol 1994;31:289-300.
32. Beviglia L, Stewart GJ, Niewiarowski S. Effect of four disintegrins on the adhesive and metastatic properties of B6F10 melanoma cells in a murine model. Oncol Res 1995;7:7-20.
33. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA. Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins. J Biol Chem 1999;274:37809-37814.
34. Vazques F, Hastings G, Ortega M-A, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angioinhibitory activity. J Biol Chem 1999;274:23349-23357.
35. Pitts WJ, Wityak J, Smallheer JM, Mousa SA, et al. Isoxazolines as potent antagonists of the integrin alpha v beta 3. J Med Chem 2000;43:27-40.
36. Batt DG, Petraitis JJ, Houghton GC, Mousa SA, et al. Disubstituted indazoles as potent antagonists of the integrin alpha v beta 3. J Med Chem 2000;43:41-58.
37. Miller WH, Alberts DP, Bhatnagar PK, et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic. J Med Chem 2000;43:22-26.
38. Allman R, Cowbum P, Mason M. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha v beta 3 integrin in human melanoma cells. Eur J Cancer 2000;36:410-422.
39. Hoekstra WJ, Poulter BL. Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr Med Chem 1998;5:195-204.
40. Pasco S, Han J, Gillery P, et al. A specific sequence of the non-collagenous domain of the cc,(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res 2000;60:467-473.
41. Duggan DE, Hutchinson JH. Ligands to the integrin receptor alpha v beta 3. Exp Opin Ther Patents 2000;10:1367-1383.
42. Miller WH, Keenan RM, Willette RN, Lark MW. Identification and in vivo efficacy of small-molecule antagonists of integrin alpha v beta 3 (the vitronectin receptor). Drug Discov Today 2000;5:397-408.
43. Klemke RL, Yebra M, Bayna E, Cheresh DA. Receptor tyrosine kinase signaling required for integrin alpha v beta 5 directed cell motility but not adhesion on vitronectin. J Cell Biol 1994;127:859-866.
44. Friedlander M, Brooks PC, Shaffer R, Kincaid SM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500-1502.
45. Albini A, Noonan D, Santi L. Angiogenesis at the interface between basic and clinical research. Intern J Biol Markers 1999;14:202-206.
46. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alpha v beta 3-targeted magnetic resonance imaging. Nat Med 1998;4:623-626.
47. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, et al. A pilot trial of Vitaxin, a humanized anti-vitonectin receptor (anti-alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biothera Radiopharmaceut 2001;16:125-132.
48. Friedlander M, Theesfeld C, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA. Involvement of integrin alpha v beta 3 and alpha v beta 5 in ocular neovascualar diseases. Proc Natl Acad Sci USA 1996;93:976.
49. Preissner KT, Kanse SM, Hammes HP. Integrin chatter and vascular function in diabetic retinopathy. Horm Metab Res 1997;29:643-645.
50. Kerr JS, Mousa SA, Slee A. avb3 integrin in angiogenesis and restenosis. Drug News Perspect 2001;14:143-150.
51. Klotz O, Park JK, Pleyer U, Hartmann C, Baatz H. Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat. Graefes Arch Clin Exp Ophthalmol 2000;238:88-93.
52. Schumacher HR, Jr., Bautista BB, Krauser RE, Mathur AK, Gall EP. Histological appearance of the synovium in early rheumatoid arthritis. Semin Arthritis Rheum 1994;23(S2):3-10.
53. Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686-1696.
54. Laiw L, Almeida M, Hart C, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle in vitro. Circ Res 1993;74:214-224.
55. Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995;95:713-724.
56. Choi ET, Engel L, Callow AD, et al. Inhibition of neointimal hyperplasia by blocking alpha v beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19:125-134.
57. Srivatsa SS, Fitzapatrick LA, Tsao PW, Mousa SA. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha v beta 3 and ospteopontin expression during neointima formation. Cardiovasc Res 1997;36:408-428.
58. Coleman KR, Braden GA, Willingham MC, Sane DC. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alpha v beta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 1999;84:1268-1276.
59. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343:881-886.
60. Fitzpatrick LA, Severson A, Edwards WD, et al. Diffuse calcification in human coronary arteries: Association of osteopontin with atherosclerosis. J Clin Invest 1994;94:1597-1604.
61. Bishop G, McPherson JA, Sanders J, Hesselbacher S, Feldman ML, Gimple LW, Powers E, Mousa SA, Sarembock IJ. Vitronectin αvβ3 receptor blockade reduces restenosis and intramural macrophage infiltration associated with a reduction in cellular adhesion molecule expression following balloon angioplasty of the atherosclerotic rabbit femoral artery. Circulation 2001;103:1906-1911.
62. Matsuno H, Stassen JM, Vermylen J, et al. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994;90:2203-2206.
63. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994;25:17894-17898.
64. Abumiya T, Lucero J, Heo JH, et al. Activated microvessels express vascular endothelial growth factor and integrin alpha v beta 3 during focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:1038-1050.
65. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, del Zoppo GJ. Integrin alpha v beta 3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol 1996;149:37-44.